<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03909022</url>
  </required_header>
  <id_info>
    <org_study_id>GermanVasc2019_023</org_study_id>
    <nct_id>NCT03909022</nct_id>
  </id_info>
  <brief_title>Assessing Best Medical Treatment Patterns of Patients With Symptomatic Peripheral Arterial Occlusive Disease in Germany</brief_title>
  <official_title>Assessing Best Medical Treatment Patterns of Patients With Symptomatic Peripheral Arterial Occlusive Disease in Germany - A GermanVasc Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GermanVasc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MDEpiNet Chapter Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposed study will be conducted to support real-world-evidence on the extent of best
      medical treatment for secondary prevention of patients with symptomatic peripheral arterial
      occlusive disease (PAOD) for prevention of worsening limb symptoms or of major adverse
      cardiovascular events. The overall objective of this study is to gain a better understanding
      of patient characteristics, treatment patterns and outcomes in PAOD patients. For this
      purpose the investigators will analyze a patient population hospitalized either with
      intermittent claudication (IC) or chronic limb-threatening ischaemia (CLTI) while taking
      prior PAOD-related diagnoses in the outpatient setting into account. In detail, we study
      differentials according to age, calendar time, sex, disease severity and hospital procedure.
      Data were extracted from available German health insurance claims.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2008</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants receiving best-medical-treatment</measure>
    <time_frame>at 12 months after discharge</time_frame>
    <description>Prevalence of the outpatient prescription of best medical treatment defined as picking up a medication at a pharmacy for a lipid-lowering, an antithrombotic, and an antihypertensive drug agent, within 12 months after index discharge for POAD according to information provided in health insurance claims data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants deceased</measure>
    <time_frame>at 5 years after discharge</time_frame>
    <description>Rate of all-cause mortality after index discharge for POAD according to information provided in health insurance claims</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lower extremity amputation</measure>
    <time_frame>at 5 years after discharge</time_frame>
    <description>Rate of lower extremity amputation after index discharge for POAD according to information provided in health insurance claims</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a myocardial infarction</measure>
    <time_frame>at 5 years after discharge</time_frame>
    <description>Rate of myocardial infarction after index discharge for POAD according to information provided in health insurance claims</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a stroke or transient ischaemic attack</measure>
    <time_frame>at 5 years after discharge</time_frame>
    <description>Rate of stroke or TIA after index discharge for POAD according to information provided in health insurance claims</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a major bleeding</measure>
    <time_frame>at 5 years after discharge</time_frame>
    <description>Rate of major bleeding provided in health insurance claims</description>
  </secondary_outcome>
  <enrollment type="Anticipated">60000</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <condition>Intermittent Claudication</condition>
  <condition>Critical Limb Ischemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients older than 18 years of age. Treated in outpatient or inpatient facilities for
        symptomatic peripheral arterial occlussive disease.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        1. First clinical diagnosis of symptomatic peripheral arterial occlusive disease
             (according to Fontaine classification, stages II, III and IV) after at least 5 years
             without such clinical diagnosis

          2. At least 18 years of age

             Exclusion Criteria:

          3. Incomplete information on sex, age, date of hospital discharge

          4. Less than 5 years of insurance membership before index stay
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian-Alexander Behrendt, MD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Hamburg-Eppendorf, Working Group GermanVasc</affiliation>
  </overall_official>
  <link>
    <url>http://germanvasc.de</url>
    <description>Website of the research group leading this project</description>
  </link>
  <reference>
    <citation>Peters F, Kreutzburg T, Kuchenbecker J, Debus ES, Marschall U, L'Hoest H, and Behrendt CA. A retrospective cohort study on the provision and outcomes of pharmacological therapy after revascularisation for peripheral arterial occlusive disease: a study protocolBMJ Surgery, Interventions, &amp; Health Technologies 2020;2:e000020. doi: 10.1136/bmjsit-2019-000020</citation>
  </reference>
  <results_reference>
    <citation>Behrendt CA, Sedrakyan A, Peters F, Kreutzburg T, Schermerhorn M, Bertges DJ, Larena-Avellaneda A, L'Hoest H, Kölbel T, Debus ES. Editor's Choice - Long Term Survival after Femoropopliteal Artery Revascularisation with Paclitaxel Coated Devices: A Propensity Score Matched Cohort Analysis. Eur J Vasc Endovasc Surg. 2020 Apr;59(4):587-596. doi: 10.1016/j.ejvs.2019.12.034. Epub 2020 Jan 8.</citation>
    <PMID>31926836</PMID>
  </results_reference>
  <results_reference>
    <citation>Kreutzburg T, Peters F, Rieß HC, Hischke S, Marschall U, Kriston L, L'Hoest H, Sedrakyan A, Debus ES, Behrendt CA. Editor's Choice - Comorbidity Patterns Among Patients with Peripheral Arterial Occlusive Disease in Germany: A Trend Analysis of Health Insurance Claims Data. Eur J Vasc Endovasc Surg. 2020 Jan;59(1):59-66. doi: 10.1016/j.ejvs.2019.08.006. Epub 2019 Nov 16.</citation>
    <PMID>31744786</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 2, 2019</study_first_submitted>
  <study_first_submitted_qc>April 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2019</study_first_posted>
  <last_update_submitted>April 11, 2020</last_update_submitted>
  <last_update_submitted_qc>April 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsklinikum Hamburg-Eppendorf</investigator_affiliation>
    <investigator_full_name>Christian Behrendt</investigator_full_name>
    <investigator_title>Head of Research Unit GermanVasc and Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Intermittent Claudication</mesh_term>
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

